After a positive Phase II trial, the company said its C. difficile vaccine candidate will advance to Phase III trials during the first half of 2017.
On Jan. 26, 2017, Pfizer released the results from Phase II clinical trials with its Clostridium difficile (C. difficile) vaccine candidate, PF-06425090. Based on the results from the Phase II trial, the company said PF-06425090 will be advancing to Phase III trials in the first half of 2017. The vaccine was granted FDA Fast Track designation in August 2014.
The randomized Phase II study examined the safety, tolerability, and immunogenicity of the vaccine in more than 850 healthy adults 65–85 years of age. The vaccine is designed to help prevent C. difficile infection by inducing a functional antibody response capable to neutralizing the two main disease-causing toxins produced by the infection. The Phase II study, evaluated the safety, tolerability, and immunogenicity of two dose levels (100 µg and 200 µg) of the C. difficile vaccine candidate on two different three-dose vaccination schedules.
“Despite improved infection control measures, C. difficile disease continues to rise, further augmenting an already urgent public health threat with particular negative impact on older adults,” said Kathrin Jansen, PhD, senior vice-president and head of Vaccine Research and Development for Pfizer in a statement. “We are very encouraged by these interim immunogenicity and safety results demonstrating robust increases in vaccine-elicited neutralizing antibodies to both toxins, that we believe could provide protection against C. difficile disease.”
Source: Pfizer
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.